Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation.

Abstract

AIM The aim of this study is to evaluate cardiotoxicity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients (pts) with cardiovascular comorbidities or coronary artery disease (CAD) risk factors. PATIENTS & METHODS We prospectively analyzed pts receiving AA in order to evaluate correlations between cardiotoxicity onset… (More)
DOI: 10.2217/fon-2017-0385

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.